Pelleting in Associated with Sodium Monensin Increases the Conjugated Linoleic Acids Concentration in the Milk of Dairy Cows Fed Canola Seeds

Combination of pelleting and monensin does not affect antioxidant properties and fatty acids in milk of grazing dairy cows supplemented with a concentrate containing soybean seeds

This study was performed with the main objective of evaluating the effect of the combination of pelleting and monensin on fatty acids (FA) composition, the concentration of total polyphenols and flavonoids, and the oxidative stability of milk in cows fed a concentrate containing soybean seeds. Eight Holstein multiparous cows were distributed in a replicated Latin square design. The four supplement treatments consisted of the combination of two factors (pelleting and monensin) and one concentrate as follows: (1) unpelleted concentrate with no monensin (CO); (2) pelleted concentrate with no monensin (PE); (3) unpelleted concentrate with 96 mg of monensin/kg of dry matter, DM (MO); and (4) pelleted concentrate with 96 mg of monensin/kg of DM (PM). There was no interaction between pelleting and monensin for milk production and concentration of milk protein, lactose, total polyphenols, flavonoids, conjugated dienes (CD), and reducing power. Fat and total solids concentration in milk were decreased when cows were fed pelleted (PE and PM) concentrates. Feeding cows with PE and PM concentrates increased the CD concentration in milk. Regarding milk FA concentration, there was no difference among treatments for total saturated, monounsaturated, and polyunsaturated FA. The most prominent result was that pelleting increased the milk concentration of omega-3 FA. Altogether, the present study suggests that the pelleting process can improve the milk fat quality by increasing the omega-3 FA, while the combination of pelleting and monensin in the diet of grazing dairy cows fed soybean-based concentrate adds no further improvements to FA profiles and oxidative stability of milk.

Does the dry cow treatment with monensin controlled release capsule affect Parmigiano Reggiano cheese production?

We investigated the effects of monensin controlled-release capsule (CRC; Kexxtone, Eli Lilly and Company Ltd., Indianapolis, IN) preventative ketosis treatment on the traditional cheesemaking process as well as the final characteristics of Parmigiano Reggiano (PR) cheese. The use of this prevention product to reduce the incidence of ketosis in transition dairy cows was approved by the European Medicines Agency in 2013. No previous studies are available concerning the effects of this treatment on prolonged-ripening cheese production such as PR. In PR cheese production, feed, feed additives, and cow treatments are strictly regulated to avoid any possible interference with traditional manufacturing processes. For these reasons, on 1 farm where all milk was used for PR cheese production, monensin CRC was administered to 33 cows, 21 d before calving in the monensin-treated group (TRT), whereas untreated cows with similar breed and parity characteristics constituted the control group (CTR). For 20 wk, milk obtained from each group and whey starter were separately managed and transported in the cheese factory, where 2 cheese wheels per group were produced daily, making 552 PR cheese wheels in total. Morning bulk tank milk composition, cheesemaking properties, and whey starter fermentation activities were analyzed twice a week. Every aspect of the cheesemaking process was recorded and the resulting cheese was evaluated after 36 h and 6, 12, and 18 mo from production for yield, texture defects, composition, and fatty acids profile. Milk from the 2 groups differed for somatic cell content (TRT = 3.04 vs. CTR = 4.06, somatic cell score), total bacterial count (TRT = 4.08 vs. CTR = 6.08 × 1,000 cfu/mL), titratable acidity (TRT = 3.66 vs. CTR = 3.72 Soxhlet-Henkel degrees/50 mL), and casein content percentage (TRT = 2.4 vs. CTR = 2.5%). Whey starter parameters were comparable between the 2 groups. Final cheese composition and organoleptic profile were not influenced by the treatment, except for C18:1 content being enhanced (TRT = 22.8 vs. CTR = 20.8% of fatty acids). Percentage of defected ripened cheese was significantly lower in the treated group, both at x-ray evaluation performed at 6 mo (TRT = 6.2 vs. CTR = 12.3%) and at the consortium inspection, performed at 12 mo of ripening (TRT = 1.5 vs. CTR = 6.5%). On the other hand, average cheese yield at 18 mo of ripening was partially reduced (TRT = 7.5 vs. CTR = 7.7%). Overall, the use of monensin CRC had no negative effect on the cheesemaking process, prolonged ripening cheese characteristics, milk composition, or whey starter quality.